Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition

Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity. The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first…

Read More

OpenAI Launches ChatGPT Health: 5 Things to Know

OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation. The post OpenAI Launches ChatGPT Health: 5 Things to Know appeared first on MedCity News.

Read More